European Journal of Cancer
Volume 43, Issue 16 , Pages 2345-2350 , November 2007

Phase III study of cyclophosphamide, doxorubicin, and etoposide compared with carboplatin and paclitaxel in patients with extensive disease small-cell lung cancer

  • Wouter K. de Jong

      Affiliations

    • Department of Pulmonology, University Medical Center Groningen, University of Groningen, P.O. Box 30.001, 9700 RB Groningen, The Netherlands
    • ,
  • Harry J.M. Groen

      Affiliations

    • Department of Pulmonology, University Medical Center Groningen, University of Groningen, P.O. Box 30.001, 9700 RB Groningen, The Netherlands
    • Corresponding Author InformationCorresponding author: Tel.: +31 (0)50 3616161; fax: +31 (0)50 3619320.
    • ,
  • Mia G.J. Koolen

      Affiliations

    • Department of Pulmonology, Academy Medical Center, Amsterdam, The Netherlands
    • ,
  • Bonne Biesma

      Affiliations

    • Department of Pulmonology, Jeroen Bosch Hospital, ‘s-Hertogenbosch, The Netherlands
    • ,
  • Luuk N.A. Willems

      Affiliations

    • Department of Pulmonology, Leiden University Medical Center, Leiden, The Netherlands
    • ,
  • Hian-Bie Kwa

      Affiliations

    • Department of Pulmonology, Onze Lieve Vrouwe Gasthuis, Amsterdam, The Netherlands
    • ,
  • Aart van Bochove

      Affiliations

    • Department of Medicine, Zaans Medisch Centrum, Zaandam, The Netherlands
    • ,
  • Harm van Tinteren

      Affiliations

    • Comprehensive Cancer Center Amsterdam, Amsterdam, The Netherlands
    • ,
  • Egbert F. Smit

      Affiliations

    • Department of Pulmonology, Vrije Universiteit Medical Center, Amsterdam, The Netherlands

Received 26 May 2007 ,Revised 13 July 2007 ,Accepted 31 July 2007.

References 

  1. Postmus PE, Scagliotti G, Groen HJ, et al. Standard versus alternating non-cross-resistant chemotherapy in extensive small cell lung cancer: an EORTC Phase III trial. Eur J Cancer. 1996;32A:1498–1503
  2. Ardizzoni A, Tjan-Heijnen VC, Postmus PE, et al. Standard versus intensified chemotherapy with granulocyte colony-stimulating factor support in small-cell lung cancer: a prospective European Organization for Research and Treatment of Cancer-Lung Cancer Group Phase III Trial-08923. J Clin Oncol. 2002;20:3947–3955
  3. Giaccone G, Dalesio O, McVie GJ, et al. Maintenance chemotherapy in small-cell lung cancer: long-term results of a randomized trial. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol. 1993;11:1230–1240
  4. Tjan-Heijnen VC, Postmus PE, Ardizzoni A, et al. Reduction of chemotherapy-induced febrile leucopenia by prophylactic use of ciprofloxacin and roxithromycin in small-cell lung cancer patients: an EORTC double-blind placebo-controlled phase III study. Ann Oncol. 2001;12:1359–1368
  5. Chute JP, Chen T, Feigal E, Simon R, Johnson BE. Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: perceptible progress. J Clin Oncol. 1999;17:1794–1801
  6. Roth BJ, Johnson DH, Einhorn LH, et al. Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. J Clin Oncol. 1992;10:282–291
  7. Noda K, Nishiwaki Y, Kawahara M, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med. 2002;346:85–91
  8. Hanna N, Bunn PA, Langer C, et al. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol. 2006;24:2038–2043
  9. Eckardt JR, von Pawel J, Papai Z, et al. Open-label, multicenter, randomized, phase III study comparing oral topotecan/cisplatin versus etoposide/cisplatin as treatment for chemotherapy-naive patients with extensive-disease small-cell lung cancer. J Clin Oncol. 2006;24:2044–2051
  10. Socinski MA, Weissman C, Hart LL, et al. Randomized phase II trial of pemetrexed combined with either cisplatin or carboplatin in untreated extensive-stage small-cell lung cancer. J Clin Oncol. 2006;24:4840–4847
  11. Groen HJ, Fokkema E, Biesma B, et al. Paclitaxel and carboplatin in the treatment of small-cell lung cancer patients resistant to cyclophosphamide, doxorubicin, and etoposide: a non-cross-resistant schedule. J Clin Oncol. 1999;17:927–932
  12. Thomas P, Castelnau O, Paillotin D, et al. Phase II trial of paclitaxel and carboplatin in metastatic small-cell lung cancer: a Groupe Francais de Pneumo-Cancerologie study. J Clin Oncol. 2001;19:1320–1325
  13. Gridelli C, Manzione L, Perrone F, et al. Carboplatin plus paclitaxel in extensive small cell lung cancer: a multicentre phase 2 study. Br J Cancer. 2001;84:38–41
  14. Calvert AH, Newell DR, Gumbrell LA, et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol. 1989;7:1748–1756
  15. Pocock SJ, Simon R. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics. 1975;31:103–115
  16. Sundstrom S, Bremnes RM, Kaasa S, et al. Second-line chemotherapy in recurrent small cell lung cancer. Results from a crossover schedule after primary treatment with cisplatin and etoposide (EP-regimen) or cyclophosphamide, epirubicin, and vincristin (CEV-regimen). Lung Cancer. 2005;48:251–261
  17. Urban T, Chastang C, Lebas FX, et al. The addition of cisplatin to cyclophosphamide-doxorubicin-etoposide combination chemotherapy in the treatment of patients with small-cell lung carcinoma: a randomized study of 457 patients. Petites Cellules Group Cancer. 1999;86:2238–2245
  18. Deppermann KM, Serke M, Oehm C, et al. Paclitaxel and carboplatin in advanced SCLC: a phase II study. Proc Am Soc Clin Oncol. 1999;18:482a
  19. Timmer-Bonte JN, de Boo TM, Smit HJ, et al. Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch Randomized Phase III Study. J Clin Oncol. 2005;23:7974–7984
  20. Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 Update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol. 2006;24:3187–3205
  21. Aapro MS, Cameron DA, Pettengell R, et al. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer. 2006;42:2433–2453

☆ This study was presented in part at the 41st Annual meeting of the American Society of Clinical Oncology, Orlando, FL, May 13–17, 2005, and at the 11th World Conference on Lung Cancer, Barcelona, Spain, July 3–6, 2005.

☆☆ Registered at www.clinicaltrials.gov, NCT00003696.

PII: S0959-8049(07)00587-4

doi: 10.1016/j.ejca.2007.07.029

European Journal of Cancer
Volume 43, Issue 16 , Pages 2345-2350 , November 2007

Article Tools

* Image Usage & Resolution